Pantoprazole

29 interactions 1 explained in plain English
Also sold as: Protonix Protonix®
About Pantoprazole

Pantoprazole is a proton-pump inhibitor used to treat heartburn and acid reflux damage by reducing stomach acid production. Read the full Pantoprazole drug information page →

Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jun 30, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Dacomitinib Ketoconazole Topical Belumosudil Octreotide Octreotide Injection Gefitinib
24 Major 5 Moderate
All (29) Major (24) Moderate (5)

Major

Pantoprazole Acalabrutinib Calquence Reduced acalabrutinib exposure Details Pantoprazole Alpelisib Piqray Increased alpelisib exposure and an increased risk of alpelisib-related adverse effects and toxicity Details Pantoprazole Belumosudil Rezurock Explained Reduced belumosudil exposure Details Pantoprazole Atezolizumab Injection Tecentriq Impaired efficacy of atezolizumab Details Pantoprazole Bosutinib Bosulif Reduced bosutinib exposure Details Pantoprazole Capecitabine Xeloda Reduction in capecitabine efficacy Details Pantoprazole Cefuroxime Ceftin® Decreased cefuroxime axetil exposure Details Pantoprazole Dacomitinib Vizimpro Reduced dacomitinib exposure Details Pantoprazole Dasatinib Phyrago Reduced dasatinib exposure Details Pantoprazole Digoxin Cardoxin® An increased risk of serious adverse reactions Details Pantoprazole Erlotinib Tarceva Reduced erlotinib exposure Details Pantoprazole Furosemide Injection Disal An increased risk of serious adverse reactions Details Pantoprazole Gefitinib Iressa Decreased exposure of gefitinib Details Pantoprazole Infigratinib Truseltiq Decreased infigratinib plasma concentrations Details Pantoprazole Ketoconazole Topical Extina® Foam Reduced ketoconazole exposure and reduced efficacy of ketoconazole Details Pantoprazole Letermovir Injection Prevymis Reduced pantoprazole exposure Details Pantoprazole Methotrexate Jylamvo Increased exposure of methotrexate and its metabolite and an increased risk of methotrexate toxicity Details Pantoprazole Methotrexate Injection Abitrexate® Increased exposure of methotrexate and its metabolite and an increased risk of methotrexate toxicity Details Pantoprazole Methylphenidate Adhansia XR® Altered pharmacodynamic and changes in release profile of methylphenidate Details Pantoprazole Methylphenidate Transdermal Patch Daytrana Altered pharmacodynamic and changes in release profile of methylphenidate Details Pantoprazole Neratinib Nerlynx Decreased neratinib solubility, absorption, and exposure Details Pantoprazole Nivolumab Injection Opdivo Reduced efficacy of nivolumab Details Pantoprazole Octreotide Bynfezia Decreased octreotide bioavailability Details Pantoprazole Octreotide Injection Bynfezia Decreased octreotide bioavailability Details

Moderate

Pantoprazole Ampicillin Amcill® Loss of ampicillin efficacy Details Pantoprazole Ampicillin Injection Omnipen-N® Loss of ampicillin efficacy Details Pantoprazole Doxycycline Injection Acticlate Reduced doxycycline efficacy Details Pantoprazole Levothyroxine Ermeza Reduced efficacy of levothyroxine and an increased risk of hypothyroidism Details Pantoprazole Mitapivat Aqvesme Reduced CYP2C19 substrate exposure Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.